Anlotinib
Anlotinib is one of the most used cancer pills in China, first approved for lung cancer after other treatments have failed and then for several rarer tumours.
Overview
Developed by Chia Tai Tianqing (Sino Biopharm); approved by the NMPA in May 2018 for advanced NSCLC after at least two lines on ALTER 0303 (439 patients: median overall survival 9.6 versus 6.3 months with placebo, hazard ratio 0.68), then for soft tissue sarcoma (2019), small cell lung cancer after two lines (2019) and medullary thyroid cancer (2020), with many combination trials alongside domestic PD-1 antibodies. Its wide use reflects NRDL listing from 2018 and a large domestic sales force as much as its effect size.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| China | 2018 | Advanced NSCLC after at least two lines of systemic therapy (ALTER 0303) |
| China | 2019 | Advanced soft tissue sarcoma after chemotherapy; small cell lung cancer after at least two lines |
| China | 2020 | Advanced medullary thyroid cancer |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Anlotinib" OR ABSTRACT:"Anlotinib" OR TITLE:"Focus V" OR ABSTRACT:"Focus V" OR TITLE:"AL3818" OR ABSTRACT:"AL3818") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Anlotinib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductDonafenib
Shares VEGF angiogenesis, Anti-angiogenic therapy, VEGF / VEGFR, Thyroid cancer and the tag china.
- ProductRivoceranib (apatinib)
Shares VEGF angiogenesis, Anti-angiogenic therapy, VEGF / VEGFR, Small-molecule kinase inhibitors and the tag china.
- InstitutionJilin Cancer Hospital
Shares Ying Cheng, Small-cell lung cancer and the tag china.
- ProductAdebrelimab
Shares Ying Cheng, Small-cell lung cancer and the tag china.
- TrialCAPSTONE-1
Shares Ying Cheng, Small-cell lung cancer and the tag china.
- ProductIcotinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- ProductGarsorasib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- ProductFurmonertinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.